Hepatitis C Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Hepatitis C Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
The model discusses in detail the impact of COVID-19 on Hepatitis C Tests market for the year 2020 and beyond. Hepatitis C is a viral infection caused by hepatitis C virus (HCV). Hepatitis C virus is a blood borne virus that causes liver disease and can cause acute and chronic hepatitis. Infection may be caused through injection drug use, transfusion of unscreened blood products, unsafe injection practices, sexual contact and from infected mother to her baby.
Diagnosis of HCV infection can be done by screening for anti-HCV antibodies along with a serological test to confirm the viral infection. Nucleic acid test for HCV ribonucleic acid (RNA) is performed in case of positive test results for anti HCV antibodies to confirm chronic infection. Since there is no vaccine available for HCV infection, the World Health Organization (WHO) recommends blood tests to screen patients that are at an increased risk of HCV infection and reducing the risk of HCV exposure in health care settings. Screening of pregnant women for HCV is standard of care in most countries and considered to be a cost-effective strategy for reducing the risk of transmission to the baby.
The Hepatitis C virus tests includes Hepatitis C Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Tests, Hepatitis C Nucleic Acid Amplification Tests (NAATs) and Multi-parameter HIV, Hepatitis B, and Hepatitis C Nucleic Acid Amplification Tests (NAATs).
Each of the covered 39 country’s color-coded and fully-sourced market models are equipped with value, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are:
Currently marketed Hepatitis C Tests and evolving competitive landscape:
– Insightful review of the key industry trends.
– Annualized total Hepatitis C Tests market revenue by segment and market outlooks from 2015-2033.
– Market level data on units, average selling prices and market values.
Global, Regional and Country level market specific insights:
– Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
– SWOT analysis for Hepatitis C Tests market.
– Competitive dynamics insights and trends provided for Hepatitis C Tests market.
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
– Country specific overview of the healthcare system.
– Country specific reimbursement policies.
– Country specific medtech regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: Abbott Laboratories, Grifols SA, F. Hoffmann-La Roche Ltd, QuidelOrtho Corp, Hologic Inc, Oswaldo Cruz Foundation, Siemens Healthineers AG, Qiagen NV, DiaSorin SpA, and others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.
Hepatitis C Tests Market Dynamics
Hepatitis C is a viral infection that causes liver inflammation and serious liver damage. Chronic Hepatitis C virus (HCV) can be cured with oral medications taken for two to six months. The incidence of HCV is expected to remain stable in most countries during the forecast period. HCV incidence is expected to increase in the US, Canada, China, and Brazil, while incidence is decreasing in Germany, Australia, and New Zealand.
Global HCV tests market growth is expected during the forecast period (post pandemic time), with the strongest development occurring in the North American and APAC regions. Strong gains are expected to occur in key markets such as the US and China, followed by India. In each country, HCV test sales are influenced by a variety of different factors, including fluctuations in disease incidence and prevalence, the number of pregnant women, sperm donations, whole blood donations, and source plasma donations.
Buy the Full Report for Additional Hepatitis C Tests Market Dynamics, Download a Free Sample Report
Hepatitis C Tests Market Segments
The key segments in the Hepatitis C tests market are Hepatitis C Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Tests, and Hepatitis C Nucleic Acid Amplification Tests (NAATs). In 2023, the Hepatitis C Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Tests segment dominated the market share. The segment is likely to dominate the market during the projected period.
Hepatitis C Tests Market Analysis by Segments, 2023 (%)
Buy the Full Report for More Segment-Wise Insights about the Hepatitis C Tests Market Segments, Download a Free Sample Report
Hepatitis C Tests Market Segmentation by Regions
The key regions in the Hepatitis C tests market are Asia-Pacific, Europe, the Middle East and Africa, North America, and South and Central America. In 2023, North America was the leading regional segment in the Hepatitis C tests market.
Strong growth is expected to occur in the North American Hepatitis C tests market over the next decade. The US and Canadian markets are both expected to grow, while a slight decline is expected in the Mexican market. The number of Hepatitis C tests performed for prevalent cases is expected to increase in all three North American countries, with the number of suspected infection cases also expected to increase in the US and Mexico. The growth in these economies is also attributed to the increases in source plasma and whole blood donations, respectively. The number of pregnant women in these two countries is also expected to increase, further augmenting the Hepatitis C tests market.
Hepatitis C tests Market Analysis by Regions, 2023 (%)
Buy the Full Report for More Regional Insights in the Hepatitis C tests Market, Download A Free Sample Report
Hepatitis C tests Market – Competitive Landscape
The key companies in the Hepatitis C tests market are Roche Diagnostics International Ltd, Quidel Corp, Siemens Healthineers AG, DiaSorin SpA, and Abbott Laboratories among others. In 2023, Roche Diagnostics International Ltd accounted for the highest Hepatitis C tests market share and value.
Hepatitis C Tests Market Analysis by Companies, 2023 (%)
Buy the Full Report for More Company-Wise Insights into the Hepatitis C Tests Market, Download a Free Sample Report
Segments Covered in this Report
Hepatitis C tests Segment Outlook ($ Million, 2015-2033)
- Hepatitis C Tests
- Hepatitis C Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Tests
- Hepatitis C Nucleic Acid Amplification Tests (NAATs)
Hepatitis C tests Regional Outlook ($ Million, 2015-2033)
- Asia-Pacific
- Europe
- Middle East and Africa
- North America
- South and Central America
Key Inclusions of the market model are –
Currently marketed Hepatitis C tests market and evolving competitive landscape –
- Insightful review of the key industry trends.
- Annualized total Hepatitis C tests market revenue by segment and market outlooks from 2015-2033.
- Market-level data on units, average selling prices, and market values.
Global, Regional and Country level market specific insights –
- Qualitative market-specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country-specific insights on the market.
- SWOT analysis for the Hepatitis C tests market.
- Competitive dynamics insights and trends provided for the Hepatitis C tests market.
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
- Country-specific overview of the healthcare system.
- Country-specific reimbursement policies.
- Country-specific medtech regulatory landscape.
Robust methodologies and sources enable the model to provide an extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real-world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: Abbott Laboratories, Grifols SA, F. Hoffmann-La Roche Ltd, QuidelOrtho Corp, Hologic Inc, Oswaldo Cruz Foundation, Siemens AG, Qiagen NV, DiaSorin SpA, and others.
Countries covered – United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.
Scope
This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for:
– CMO executives who must have deep understanding of the Hepatitis C Tests market place to make strategic planning and investment decisions.
– Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
– Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.
Reasons to Buy
The model will enable you to:
– Understand the impact of COVID-19 on Hepatitis C Tests market.
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving Hepatitis C Tests market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Hepatitis C Tests market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
– Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
– Track device sales in the global and country-specific Hepatitis C Tests market from 2015-2033.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Grifols SA
F. Hoffmann-La Roche Ltd
QuidelOrtho Corp
Hologic Inc
Oswaldo Cruz Foundation
Qiagen NV
DiaSorin SpA
Siemens Healthineers AG
Frequently asked questions
-
What was the Hepatitis C tests market size in 2023?
The Hepatitis C tests market size was $1.41 billion in 2023.
-
What will the CAGR of the Hepatitis C tests market be during 2023-2033?
The Hepatitis C tests will grow at a CAGR of more than 2% during 2023-2033.
-
Which was the leading segment in the Hepatitis C tests market in 2023?
Prothrombin Time Point of Care (POC) tests segment was leading the Hepatitis C tests market in 2023.
-
Which region held the largest share of the Hepatitis C tests market in 2023?
North America was the largest regional market for Hepatitis C tests in 2023.
-
Which are the leading players in the Hepatitis C tests market?
The key companies in the Hepatitis C tests market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Siemens AG, Diagnostica Stago SAS, Werfen Life Group SAU, Bio-Rad Laboratories Inc, bioMerieux SA, Quidelortho Corp, Danaher Corp, Revvity Inc, and others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.